TrialFuture oncology (London, England)2025
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.
Andrew J Armstrong et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this paperpooled itcites it